Literature DB >> 16107437

CDC international HIV prevention research activities among injection drug users in Thailand and Russia.

Alan E Greenberg1, Jordan Tappero, Kachit Choopanya, Frits van Griensven, Mike Martin, Suphak Vanichseni, Scott Santibanez, Valerie Molotilov, Shannon Hader, Laura N Broyles.   

Abstract

The Centers for Disease Control and Prevention (CDC) has participated in collaborative HIV prevention research activities in injection drug users (IDUs) with the Bangkok Metropolitan Administration (BMA) in Bangkok, Thailand, from 1995 to the present and with the Orel AIDS Center in Orel Oblast, Russia, from 2001 to 2003. Studies in Bangkok have included an HIV prevention trial preparatory cohort from 1995 to 1998, a seroconverter cohort from 1998 to the present, a phase III trial of the AIDSVAX B/E gp120 HIV vaccine from 1999 to 2003, and a phase II/III HIV prophylaxis trial with tenofovir scheduled to begin in 2005. Activities in Orel included a review of HIV surveillance data in 2001, focus group discussions and a case-control study with HIV-infected and -uninfected IDUs in 2001, a cross-sectional study with the female sex partners of male IDUs in 2002, and a community outreach intervention in 2002-2003. In Bangkok, 1,209 IDUs were enrolled in the preparatory cohort which revealed an HIV incidence of 5.8% per 100 person-years; 133 HIV-infected IDUs have been followed in the seroconverter cohort with >85% follow-up and HIV and tuberculosis care provided; 2,546 IDUs were enrolled in the HIV vaccine efficacy trial which was successfully completed with a follow-up rate of >95%, although the vaccine was not shown to be effective at reducing HIV incidence; and 1,600 IDUs will be enrolled in the daily tenofovir HIV prophylaxis trial in 2005. In Orel, initial focus group discussions and epidemiologic studies revealed low HIV knowledge and high rates of unsafe injecting and sexual practices among IDUs and their female sex partners; and educational campaigns and the community outreach intervention were developed and implemented. A steady decline in new HIV infections in IDUs was then observed in Orel in 2002-2003. CDC has participated in the conduct of successful collaborative HIV prevention research activities in Thailand and Russia over the past decade. The establishment of long-term relationships with in-country public health and community partners has been instrumental in the success of these efforts.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107437     DOI: 10.1093/jurban/jti105

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  18 in total

1.  Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand.

Authors:  S Vanichseni; D Kitayaporn; T D Mastro; P A Mock; S Raktham; D C Des Jarlais; S Sujarita; L O Srisuwanvilai; N L Young; C Wasi; S Subbarao; W L Heyward; L Esparza; K Choopanya
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand.

Authors:  Frits van Griensvan; Jaranit Keawkungwal; Jordan W Tappero; Udomsak Sangkum; Punnee Pitisuttithum; Suphak Vanichseni; Pravan Suntharasamai; Karin Orelind; Carolyn Gee; Kachit Choopanya
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

3.  Viral load differences in early infection with two HIV-1 subtypes.

Authors:  D J Hu; S Vanichseni; T D Mastro; S Raktham; N L Young; P A Mock; S Subbarao; B S Parekh; L Srisuwanvilai ; R Sutthent; C Wasi; W Heneine; K Choopanya
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

4.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

5.  Implications of the growing HIV-1 epidemic for tuberculosis control in Russia.

Authors:  B Kazionny; C D Wells; H Kluge; N Gusseynova; V Molotilov
Journal:  Lancet       Date:  2001-11-03       Impact factor: 79.321

6.  Temporal trends in the HIV-1 epidemic in Russia: predominance of subtype A.

Authors:  Aleksei F Bobkov; Elena V Kazennova; Ludmila M Selimova; Tatyana A Khanina; Grigory S Ryabov; Marina R Bobkova; Anna L Sukhanova; Aleksei V Kravchenko; Natalia N Ladnaya; Jonathan N Weber; Vadim V Pokrovsky
Journal:  J Med Virol       Date:  2004-10       Impact factor: 2.327

7.  Rapid increase in HIV rates--Orel Oblast, Russian Federation, 1999-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-07-18       Impact factor: 17.586

8.  Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users.

Authors:  Artur Ramos; Dale J Hu; Lily Nguyen; Kim-Oanh Phan; Suphak Vanichseni; Nattawan Promadej; Kachit Choopanya; Margaret Callahan; Nancy L Young; Janet McNicholl; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  New HIV type 1 CRF01_AE/B recombinants displaying unique distribution of breakpoints from incident infections among injecting drug users in Thailand.

Authors:  Artur Ramos; Lily Nguyen; Dale J Hu; Suphak Vanichseni; Kachit Choopanya; Nancy L Young; Jordan W Tappero; Timothy D Mastro; Thomas M Folks; Shambavi Subbarao
Journal:  AIDS Res Hum Retroviruses       Date:  2003-08       Impact factor: 2.205

10.  [HIV-infection in Russia: a prediction].

Authors:  V V Pokrovskiĭ
Journal:  Vopr Virusol       Date:  2004 May-Jun
View more
  3 in total

Review 1.  Behavior change and health-related interventions for heterosexual risk reduction among drug users.

Authors:  Salaam Semaan; Don C Des Jarlais; Rob Malow
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

Review 2.  The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs.

Authors:  Stefan D Baral; Susanne Strömdahl; Chris Beyrer
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

Review 3.  Tuberculosis and illicit drug use: review and update.

Authors:  Robert G Deiss; Timothy C Rodwell; Richard S Garfein
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.